Haloperidol induces apoptosis via the σ2 receptor system and Bcl-XS

Pharmacogenomics Journal

Volumn 6, Issue 4, 2006, Pages 279-288

  Wei, Z ^a   Mousseau, D D ^a   Dai, Y ^a   Cao, X ^a   Li, X M ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN[1-40]; CYTOCHROME C; DOPAMINE 2 RECEPTOR; GUANIDINE DERIVATIVE; HALOPERIDOL; N ALLYLNORMETAZOCINE; NEUROLEPTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLANZAPINE; PROGESTERONE; PROTEIN BAX; PROTEIN BCL XS; PROTEIN P53; QUETIAPINE; REGULATOR PROTEIN; RIMCAZOLE; SIGMA 2 OPIATE RECEPTOR; SIGMA OPIATE RECEPTOR; SULPIRIDE; UNCLASSIFIED DRUG; VOLTAGE GATED CHANNEL FORMING PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL STRAIN; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOSOL; CYTOTOXICITY; DRUG RECEPTOR BINDING; HISTOPATHOLOGY; MITOCHONDRION; MOUSE; NERVE CELL; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; RAT;

EID: 33746576243     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500373     Document Type: Article

References (48)

1. Wyatt RJ, Damiani LM, Henter ID. First-episode schizophrenia. Early intervention and medication discontinuation in the context of course and treatment. Br J Psychiatry 1998; 172: 77-83.
2. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005; 62: 361-370.
3. Dewey KJ, Fibiger HC. The effects of dose and duration of chronic pimozide administration on dopamine receptor supersensitivity. Naunyn Schmiedebergs Arch Pharmacol 1983; 322: 261-270.
4. Galili-Mosberg R, Gil-Ad I, Weizman A, Melamed E, Offen D. Haloperidol-induced neurotoxicity - possible implications for tardive dyskinesia. J Neural Transm 2000; 107: 479-490.
5. Bowen WD. σ-Receptors: Recent advances and new clinical potentials. Pharm Acta Helv 2000; 74: 211-218.
6. Quirion R, Bowen WD, Itzhak Y, Junien JL, Musacchio JM, Rothman RB et al. A proposal for the classification of σ binding sites. Trends Pharmacol Sci 1992; 13: 85-86.
7. Hayashi T, Su TP. σ-1 receptor ligands: Potential in the treatment of neuropsychiatric disorders. CNS Drugs 2004; 18: 269-284.
8. Su TP, London ED, Jaffe JH. Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. Science 1988; 240: 219-221.
9. Boyer EW. Dextromethorphan abuse. Pediatr Emerg Care 2004; 20: 858-863.
10. Gil-Ad I, Shtaif B, Shiloh R, Weizman A. Evaluation of the neurotoxic activity of typical and atypical neuroleptics: Relevance to iatrogenic extrapyramidal symptoms. Cell Mol Neurobiol 2001; 21: 705-716.
11. Crawford KW, Bowen WD. σ-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res 2002; 62: 313-322.
12. Vilner BJ, Bowen WD. Modulation of cellular calcium by σ-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells. J Pharmacol Exp Ther 2000; 292: 900-911.
13. Chan SL, Yu VC. Proteins of the bcl-2 family in apoptosis signalling: from mechanistic insights to therapeutic opportunities. Clin Exp Pharmacol Physiol 2004; 31: 119-128.
14. Lindenboim L, Yuan J, Stein R. Bcl-xS and Bax induce different apoptotic pathways in PC12 cells. Oncogene 2000; 19: 1783-1793.
15. Lindenboim L, Schlipf S, Kaufmann T, Borner C, Stein R. Bcl-x(S) induces an NGF-inhibitable cytochrome c release. Exp Cell Res 2004; 297: 392-403.
16. Wei Z, Mousseau DD, Richardson JS, Dyck LE, Li XM. Atypical antipsychotics attenuate neurotoxicity of β-amyloid (25-35) by modulating Bax and Bcl-X(L/S) expression and localization. J Neurosci Res 2003; 74: 942-947.
17. Post A, Holsboer F, Behl C. Induction of NF-κB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: suppression of NF-κB and neuroprotection by antioxidants. J Neurosci 1998; 18: 8236-8246.
18. Post A, Rucker M, Ohl F, Uhr M, Holsboer F, Almeida OF et al. Mechanisms underlying the protective potential of α-tocopherol (vitamin E) against haloperidol-associated neurotoxicity. Neuropsychopharmacology 2002; 26: 397-407.
19. Martinou JC, Green DR. Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2001; 2: 63-67.
20. Musacchio JM, Klein M, Paturzo JJ. Effects of dextromethorphan site ligands and allosteric modifiers on the binding of (+)-[3H]3-(-3-hydroxyphenyl)-N(1-propyl)piperidine. Mol Pharmacol 1989; 35: 1-5.
21. Walker JM, Bowen WD, Walker FO, Matsumoto RR, De Costa B, Rice KC. Sigma receptors: Biology and function. Pharmacol Rev 1990; 42: 355-402.
22. Hellewell SB, Bowen WD. A sigma-like binding site in rat pheochromocytoma (PC12) cells: Decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain. Brain Res 1990; 527: 244-253.
23. Gilmore DL, Liu Y, Matsumoto RR. Review of the pharmacological and clinical profile of rimcazole. CNS Drug Rev 2004; 10: 1-22.
24. Devanand DP, Marder K, Michaels KS, Sackeim HA, Bell K, Sullivan MA et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry 1998; 155: 1512-1520.
25. Mousseau DD, Chapelsky S, De Crescenzo G, Kirkitadze MD, Magoon J, Inoue S et al. A direct interaction between transforming growth factor (TGF)-βs and amyloid-β protein affects fibrillogenesis in a TGF-β receptor-independent manner. J Biol Chem 2003; 278: 38715-38722.
26. Waddington JL, Kapur S, Remington GJ. The neuroscience and clinical psychopharmacology of first- and second-generation antipsychotic drugs. In: Hirsch SR, Weinberger DR (eds). Schizophrenia, 2nd edn. Blackwell Science: Oxford, 2003, pp 421-441.
27. Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E et al. Purification, molecular cloning, and expression of the mammalian σ1-binding site. Proc Natl Acad Sci USA 1996; 93: 8072-8077.
28. Korpi ER, Kleinman JE, Costakos DT, Linnoila M, Wyatt RJ. Reduced haloperidol in the post-mortem brains of haloperidol-treated patients. Psychiatry Res 1984; 11: 259-269.
29. Vilner BJ, de Costa BR, Bowen WD. Cytotoxic effects of σ ligands: σ receptor-mediated alterations in cellular morphology and viability. J Neurosci 1995; 15: 117-134.
30. i in colon and mammary adenocarcinoma cells. Biochem Biophys Res Commun 1996; 219: 219-226.
31. Braun T, Dar S, Vorobiov D, Lindenboim L, Dascal N, Stein R. Expression of Bcl-x(S) in Xenopus oocytes induces BH3-dependent and caspase-dependent cytochrome c release and apoptosis. Mol Cancer Res 2003; 1: 186-194.
32. Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002; 297: 259-263.
33. Vander Heiden MG, Thompson CB. Bcl-2 proteins: Regulators of apoptosis or of mitochondrial homeostasis? Nat Cell Biol 1999; 1: E209-E216.
34. Martinou JC, Desagher S, Antonsson B. Cytochrome c release from mitochondria: All or nothing. Nat Cell Biol 2000; 2: E41-E43.
35. Kuwana T, Mackey MR, Perkins G, Ellisman MH, Latterich M, Schneiter R et al. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 2002; 111: 331-342.
36. Mitra RS, Benedict MA, Qian D, Foreman KE, Ekhterae D, Nickoloff BJ et al. Killing of sarcoma cells by proapoptotic Bcl-X(S): Role of the BH3 domain and regulation by Bcl-X(L). Neoplasia 2001; 3: 437-445.
37. Lezoualc'h F, Rupprecht R, Holsboer F, Behl C. Bcl-2 prevents hippocampal cell death induced by the neuroleptic drug haloperidol. Brain Res 1996; 738: 176-179.
38. Brent PJ, Pang GT. σ binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture. Eur J Pharmacol 1995; 278: 151-160.
39. Bermack JE, Debonnel G. Distinct modulatory roles of sigma receptor subtypes on glutamatergic responses in the dorsal hippocampus. Synapse 2005; 55: 37-44.
40. Gross A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 1998; 17: 3878-3885.
41. Hinz M, Loser P, Mathas S, Krappmann D, Dorken B, Scheidereit C. Constitutive NF-κB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 2001; 97: 2798-2807.
42. Kawamura K, Kimura Y, Tsukada H, Kobayashi T, Nishiyama S, Kakiuchi T et al. An increase of σ receptors in the aged monkey brain. Neurobiol Aging 2003; 24: 745-752.
43. Reddy DS, Kaur G, Kulkarni SK. Sigma (σ1) receptor mediated anti-depressant-like effects of neurosteroids in the Porsolt forced swim test. NeuroReport 1998, 9: 3069-3073.
44. Beuzen JN, Taylor N, Wesnes K, Wood A. A comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers. J Psychopharmacol 1999; 13: 152-158.
45. Gil-Ad I, Shtaif B, Levkovitz Y, Dayag M, Zeldich E, Weizman A. Characterization of phenothiazine-induced apoptosis in neuroblastoma and glioma cell lines: Clinical relevance and possible application for brain-derived tumors. J Mol Neurosci 2004; 22: 189-198.
46. Phan VL, Urani A, Sandillon F, Privat A, Maurice T. Preserved sigma1 (σ1) receptor expression and behavioral efficacy in the aged C57BL/6 mouse. Neurobiol Aging 2003; 24: 865-881.
47. Urani A, Romieu P, Roman FJ, Yamada K, Noda Y, Kamei H et al. Enhanced antidepressant efficacy of σ1 receptor agonists in rats after chronic intracerebroventricular infusion of β-amyloid-(1-40) protein. Eur J Pharmacol 2004; 486: 151-161.
48. Yao A, Nguyen TV, Pike CJ. β-Amyloid-induced neuronal apoptosis involves c-Jun N-terminal kinase-dependent downregulation of Bcl-w. J Neurosci 2005; 25: 1149-1158.